MCK Stock Overview
Provides healthcare services in the United States and internationally. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Narratives bring a range of perspectives from our community.
McKesson Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$579.74 |
52 Week High | US$637.51 |
52 Week Low | US$451.54 |
Beta | 0.50 |
1 Month Change | -6.97% |
3 Month Change | 20.66% |
1 Year Change | 27.64% |
3 Year Change | 136.30% |
5 Year Change | 322.64% |
Change since IPO | 3,413.58% |
Recent News & Updates
Investors Still Waiting For A Pull Back In McKesson Corporation (NYSE:MCK)
Dec 19McKesson's (NYSE:MCK) Soft Earnings Don't Show The Whole Picture
Nov 14Recent updates
Investors Still Waiting For A Pull Back In McKesson Corporation (NYSE:MCK)
Dec 19McKesson's (NYSE:MCK) Soft Earnings Don't Show The Whole Picture
Nov 14McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Nov 09McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Oct 09McKesson: The Correction Is Not Over
Sep 10McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing
Aug 22McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Jul 04With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08McKesson: Still Trading For A Huge Discount
Sep 06McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 015 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Shareholder Returns
MCK | US Healthcare | US Market | |
---|---|---|---|
7D | 1.7% | -1.0% | -2.7% |
1Y | 27.6% | -10.2% | 23.4% |
Return vs Industry: MCK exceeded the US Healthcare industry which returned -10.2% over the past year.
Return vs Market: MCK exceeded the US Market which returned 23.4% over the past year.
Price Volatility
MCK volatility | |
---|---|
MCK Average Weekly Movement | 4.4% |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MCK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MCK's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1833 | 48,000 | Brian Tyler | www.mckesson.com |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
McKesson Corporation Fundamentals Summary
MCK fundamental statistics | |
---|---|
Market cap | US$73.59b |
Earnings (TTM) | US$2.54b |
Revenue (TTM) | US$330.19b |
29.0x
P/E Ratio0.2x
P/S RatioIs MCK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MCK income statement (TTM) | |
---|---|
Revenue | US$330.19b |
Cost of Revenue | US$317.29b |
Gross Profit | US$12.89b |
Other Expenses | US$10.36b |
Earnings | US$2.54b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 19.98 |
Gross Margin | 3.90% |
Net Profit Margin | 0.77% |
Debt/Equity Ratio | -208.9% |
How did MCK perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield13%
Payout RatioDoes MCK pay a reliable dividends?
See MCK dividend history and benchmarksMcKesson dividend dates | |
---|---|
Ex Dividend Date | Dec 02 2024 |
Dividend Pay Date | Jan 02 2025 |
Days until Ex dividend | 21 days |
Days until Dividend pay date | 10 days |
Does MCK pay a reliable dividends?
See MCK dividend history and benchmarksCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 04:16 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
McKesson Corporation is covered by 41 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
David Toung | Argus Research Company |
Gregory Bolan | Avondale Partners |
Eric Coldwell | Baird |